Lu-177-PSMA-617: another update

Because there is great interest in systemic therapies for metastatic prostate cancer, we want to provide readers with the latest news about the 177Lu PSMA-617 trials in Germany. … READ MORE …

Data from the Phase III clinical trial of ipilimumab

Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.

Non-rising PSA but radiographic progression in men on treatment with enzalutamide

A recent presentation at the European Society of Medical Oncology (ESMO) annual meeting in Copenhagen, Denmark, has suggested that some men on treatment with enzalutamide (Xtandi) may have radiographic progression of their cancer even though there is no increase in their PSA levels. … READ MORE …

Combination therapy with radium-223 and abiraterone acetate in mCRPC

We understand from the manufacturers that the so-called ERA-223 trial — a randomized, double-blind, multi-center, Phase III trial of radium-223 acetate (Xofigo) + abiraterone acetate (Zytiga) + prednisone compared to a placebo + abiraterone acetate + prednisone — is now fully enrolled. … READ MORE …

Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Custirsen shows no benefit in combination with cabazitaxel in mCRPC

Early this morning, OncoGenex announced the result of final analysis of data from the Phase III AFFINITY trial of custirsen + cabazitaxel + prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel chemotherapy. … READ MORE …

Planning out personalized therapy for metastatic prostate cancer

A new paper from researchers at the University of Santa Cruz and UCLA, just published in the journal Cell, has laid out the beginnings of a method to identify personalizable forms of therapy for men with metastatic forms of prostate cancer. … READ MORE …